Leaflet thrombosis after transcatheter aortic valve implantation: a case report

  • Maja Rojko International center for cardiovascular diseases, MC Medicor, Izola, Slovenia
  • Nataša Černič Šuligoj International center for cardiovascular diseases, MC Medicor, Izola, Slovenia
  • Branko Cvetičanin International center for cardiovascular diseases, MC Medicor, Izola, Slovenia
  • Metka Zorc International center for cardiovascular diseases, MC Medicor, Izola, Slovenia
  • Oscar Mendiz International center for cardiovascular diseases, MC Medicor, Izola, Slovenia
  • Marko Noč International center for cardiovascular diseases, MC Medicor, Izola, Slovenia
DOI: https://doi.org/10.6016/ZdravVestn.2893
Keywords: aortic stenosis, transcatheter aortic valve implantation, leaflet thrombosis, anticoagulant therapy

Abstract

We herein report the case of a 80-year old man with symptomatic degenerative aortic stenosis (peak gradient 58 mmHg, mean gradient 38 mmHg, valve area 0.9 cm2) and haemodynamically significant left main coronary artery (LM) and anterior descending artery (LAD) stenosis with fractional flow reserve of 0.72. Because of the age and significant degenerative spine disorder, the patient refused open heart surgery. We first performed percutaneous coronary intervention (PCI) on the LM and LAD, which was followed by staged transcatheter aortic valve implantation (TAVI) with self- expandable device. There was no significant aortic regurgitation and mean aortic gradient was 12 mmHg. After 4 months, mean gradient increased to 23 mmHg and this was associated with worsening of the patient’s exercise capacity. Computed contrast-enhanced tomography of the aorta showed thrombosis of the left and non-coronary cusps with decreased leaflet mobility. Stents in the LM and LAD were widely patent without significant in-stent restenosis. Acetylsalicilic acid was stopped and coumadin added to clopidogrel. After 4 months, mean gradient was 9 mmHg. After additional 3 months of anticoagulation therapy, it was 12 mmHg. Oral anticoagulation was therefore stopped and acetylsalicylic acid restarted.

Downloads

Download data is not yet available.

References

De Backer O, Bieliauskas G, Søndergaard L. Current status and future perspectives for transcatheter and surgical aortic valve replacement: the role of aortic valve surgery in the era of transcatheter-based therapies. EuroIntervention. 2018 Oct;14(9):e965–7. https://doi.org/10.4244/EIJV14I9A172 PMID:30307396

Deutsch MA, Scotten LN, Siegel R, Lange R, Bleiziffer S. Leaflet thrombosis and clinical events after TAVR: are paravalvular leaks a crucial trigger? EuroIntervention. 2018 Aug;14(6):716–7. https://doi.org/10.4244/EIJ-D-18-00348L PMID:30122662

Rashid HN, Cameron JD, Brown AJ. Activation of the coagulation cascade and the role of paravalvular leak in the development of leaflet thrombosis following transcatheter aortic valve replacement. EuroIntervention. 2018 Aug;14(6):718–9. https://doi.org/10.4244/EIJ-D-18-00348R PMID:30122663

Vavuranakis M, Kalogeras K, Kolokathis AM, Vrachatis D, Magkoutis N, Siasos G, et al. Antithrombotic therapy in TAVI. J Geriatr Cardiol. 2018 Jan;15(1):66–75. PMID:29434628

Mylotte D, Andalib A, Thériault-Lauzier P, Dorfmeister M, Girgis M, Alharbi W, et al. Transcatheter heart valve failure: a systematic review. Eur Heart J. 2015 Jun;36(21):1306–27. https://doi.org/10.1093/eurheartj/ehu388 PMID:25265974

Ruparelia N. Oral Anticoagulant Therapy for Early Post-TAVI Thrombosis. Interv Cardiol. 2018 Jan;13(1):33–6. PMID:29593834

Testa L, Latib A. Assessing the Risk of Leaflet Motion Abnormality Following Transcatheter Aortic Valve Implantation. Interv Cardiol. 2018 Jan;13(1):37–9. PMID:29593835

Published
2019-10-06
How to Cite
1.
Rojko M, Černič Šuligoj N, Cvetičanin B, Zorc M, Mendiz O, Noč M. Leaflet thrombosis after transcatheter aortic valve implantation: a case report. TEST ZdravVestn [Internet]. 6Oct.2019 [cited 16Apr.2024];88(7-8):370-5. Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/2893
Issue
Vol 88 No 7-8 (2019): July – August
Section
Case report, short scientific article

Copyright (c) 2019 Slovenian Medical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.